Cara Therapeutics, Inc. CARA
Set alert
At close · Apr 15
52-week range unavailable
- YTD
- -71.02%
- 1 year
- -79.19%
- Open
- 4.80
- Prev close
- 5.32
- Mkt cap
- 8.11M
- Vol
- 236.84K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.28
- High
- 5.52
- Forward P/E
- -0.59
- Beta
- 0.68
- Short ratio
- 2.20
- Inst. own
- 28.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.29152
- 200-d avg
- 0.46241
- 1y target
- 1.01
2Y chart
Events in this range
- Aug 7, 2023Earnings: -0.58; estimate -0.56; surprise -3.57%
- Nov 13, 2023Earnings: -0.52; estimate -0.53; surprise 1.89%
- Mar 4, 2024Earnings: -0.59; estimate -0.57; surprise -3.51%
- May 13, 2024Earnings: -0.56; estimate -0.38; surprise -47.37%
- May 14, 2024Rating: Needham · Buy → Buy
- May 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- May 23, 2024Rating: Needham · Buy → Buy
- Jun 13, 2024Downgrade: Needham · Buy → Hold
- Jun 13, 2024Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jun 13, 2024Downgrade: Canaccord Genuity · Buy → Hold
- Aug 14, 2024Earnings: -0.37; estimate -0.29; surprise -27.59%
- Nov 14, 2024Earnings: -0.15; estimate -0.25; surprise 40%
- Dec 31, 2024Split: 1 for 12
Signals (84)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 3, 2025 | 1 year ago |
| SMA: Bullish | Apr 2, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| SMA: Bullish | Mar 5, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| SMA: Bearish | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| SMA: Bullish | Jan 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| SMA: Bearish | Jan 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
Newest 20 of 84.
Key statistics
- Market cap
- 25.09M
- Enterprise value
- 7.61M
- Trailing P/E
- 0.00
- Forward P/E
- -0.59
- PEG ratio
- 0.00
- Price / sales
- 2.28
- Price / book
- 0.44
- EPS (TTM)
- -1.75
- Beta
- 0.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 11.00M
- Revenue growth
- -85.70%
- Free cash flow
- -47.50M
- Total cash
- 56.62M
- Total debt
- 47.16M
- Return on equity
- -184.32%
- Shares outstanding
- 54.86M
- Short % of float
- 2.00%
- 50-day average
- 0.29152
- 200-day average
- 0.46241
Analyst view
Consensus: hold
- Target (low)
- 1.00
- Target (mean)
- 1.01
- Target (high)
- 1.02
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.25 | -0.15 | +0.10 | +40.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | -0.37 | -0.08 | -27.59% |
| May 13, 2024 | Mar 1, 2024 | -0.38 | -0.56 | -0.18 | -47.37% |
| Mar 4, 2024 | Dec 1, 2023 | -0.57 | -0.59 | -0.02 | -3.51% |
| Nov 13, 2023 | Sep 1, 2023 | -0.53 | -0.52 | +0.01 | +1.89% |
| Aug 7, 2023 | Jun 1, 2023 | -0.56 | -0.58 | -0.02 | -3.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2024 | Canaccord Genuity | down | Buy | Hold |
| Jun 13, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 13, 2024 | Needham | down | Buy | Hold |
| May 23, 2024 | Needham | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | Needham | reit | Buy | Buy |
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- caratherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CARA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOUDREAU HELEN M. | Director | Stock Award(Grant) | Jun 3, 2024 | 150,647 |
| GONCALVES JOANA | Officer | Sale | Apr 4, 2024 | 53,365 |
| IVES JEFFREY L | Director | Stock Award(Grant) | Jun 3, 2024 | 198,485 |
| MAYNARD RYAN D | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2024 | 13,500 |
| MENZAGHI FREDERIQUE | Officer | Stock Award(Grant) | Jan 31, 2024 | 167,247 |
| POSNER CHRISTOPHER | Chief Executive Officer | Sale | Nov 3, 2024 | 168,768 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.10% | 2,248,911 | 1.03M | Sep 29, 2024 |
| Chescapmanager LLC | 3.10% | 1,702,110 | 778.54K | Sep 29, 2024 |
| Farallon Capital Management LLC | 2.84% | 1,556,251 | 711.83K | Sep 29, 2024 |
| Disciplined Growth Investors, Inc. | 2.03% | 1,113,043 | 509.11K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.02% | 1,108,931 | 507.23K | Sep 29, 2024 |
| Two Sigma Advisers, LP | 1.58% | 866,300 | 396.25K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.47% | 1,354,313 | 619.46K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 645,753 | 295.37K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 261,602 | 119.66K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.41% | 224,141 | 102.52K | Aug 30, 2024 |
| Vanguard Health Care Index Fund | 0.30% | 165,236 | 75.58K | Aug 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.28% | 155,032 | 70.91K | Oct 30, 2024 |